Coverage summary
Aardvark Labs Capital Research has covered AbbVie (ABBV) since August 1, 2025. The company is in the Healthcare sector. This page lists 6 reports: 6 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published November 1, 2026. That report moved the rating from Hold to Underperform. The rating has changed 3 times since coverage began.
Translations: 5 in Chinese.
The Excel model for ABBV holds 22 quarters and 5 fiscal years of history and 10 quarters and 5 fiscal years of projections. It was last updated October 19, 2026.
Rating history
All ABBV reports
Recap: Q3 2026
Promises Kept, Price Paid in Advance: A Clean Beat-and-Raise Meets a Stock That Has Run Through Our Bull Case
Recap: Q2 2026
The Upgrade Worked, and That Is the Problem: A 23% Run, a Guide That Finally Moved Down, and an Aesthetics Trough That Un-Troughed
Recap: Q1 2026
The Confirming Quarter Arrives: Aesthetics Troughs, the Engines Re-Accelerate, and the Tape Finally Rewards the Beat — Upgrading to Outperform After Three Disciplined Holds.
Recap: Q4 2025
A Beat-and-Raise the Tape Sold Again: 2026’s Re-Acceleration Is Half-Funded by an IPR&D Definition Change — Maintaining Hold, One Clean Quarter From an Upgrade
Recap: Q3 2025
A $1.50 IPR&D Charge Makes a Strong Quarter Look Like a Collapse — But the Real Story Is a 21% Run-Up Meeting a Full Price. Maintaining Hold.
Recap: Q2 2025
The Ex-Humira Engine Is Firing on All Cylinders, But a +4% Gap That Faded to Flat Tells You the Price Already Knows It — Initiating at Hold